Treatment of hypertension using the three drugs – olmesartan, amlodipine, and hydrochlorothiazide gives better results than dual therapy. These results of clinical trial TRINITY presented at the annual meeting of the American Society of Hypertension.
A multicenter phase III clinical study TRINITY (Triple Therapy with Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide in Hypertension Patients Study) conducted in a group of 2,492 patients with moderate or severe hypertension. The aim was to compare the efficacy of combination therapy of antihypertensive drugs from three different classes of therapeutic effectiveness of treatment with two different drugs. Patients were randomly divided into four groups: one received olmesartan 40 mg together with 10 mg of amlodipine and hydrochlorothiazide (HCTZ) 25 mg (n = 627), olmesartan and amlodipine other at the same dose (n = 628), third olmesartan and HCTZ (n = 637), and the fourth amlodipine and HCTZ (n = 600). Assessed primary endpoint was change in diastolic blood pressure after 12 weeks of treatment compared to baseline pressure.
It was found that the triple combination therapy resulted in a reduction hypotensive diastolic blood pressure by an average of 21.8 mmHg, whereas treatment with the two drugs reduced the patients’ blood pressure of 15.1 – 18.0 mmHg, depending on the treatment regimen used. For the reduction of systolic blood pressure amounted to 37.1 mmHg, and in the treatment of triple 27,5-30,0 mmHg at different dual therapies. Furthermore medoxomil group, amlodipine and HCTZ 69.9 percent at. patients’ blood pressure was reached in accordance with the therapeutic target, ie below 140/90 mmHg. Among patients treated with two drugs therapeutic target was achieved in 41.1 – 53.4 percent. The results were independent of gender, age and race of patients. All regimens were similarly well tolerated by study participants.
The results of the clinical trial were presented at this year’s TRINITY scientific congress of the American Society of Hypertension (ASH, American Society of Hypertension), which was held in early May in New York.